Ashly E Jordan

Dr. Ashly E Jordan

Center for Drug Use and HIV/HCV Research
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
AJAshly E Jordan
Ashly E Jordan
DJDon C. Des Jarlais
Don C. Des Jarlais
KAKamyar Arasteh
Kamyar Arasteh
CMCourtney McKnight
Courtney McKnight
DNDenis Nash
Denis Nash
DPDavid C. Perlman
David C. Perlman

1 June 2017 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
AJAshly E Jordan
Ashly E Jordan
NBNatalie A. Blackburn
Natalie A. Blackburn
DJDon C. Des Jarlais
Don C. Des Jarlais
HHHolly Hagan
Holly Hagan


26 March 2014 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
HHHolly Hagan
Holly Hagan
JNJoshua Neurer
Joshua Neurer
AJAshly E Jordan
Ashly E Jordan
DJDon C Des Jarlais
Don C Des Jarlais
JWJennifer Wu
Jennifer Wu
JKJason Kessler
Jason Kessler
Outbreaks of hepatitis C virus (HCV) infection have been reported in HIV-positive men who have sex with men (MSM) in North America, Europe and Asia. Transmission is believed to be the result of exposure to blood during sexual contact. In those infected with HIV, acute HCV infection is more likely to become chronic, treatment for both HIV and HCV is more complicated and HCV disease progression may be accelerated. There is a need for systematic reviews and meta-analyses to synthesize the epidemiology, prevention and methods to control HCV infection in this population.

18 December 2017 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
AJAshly E Jordan
Ashly E Jordan
DPDavid C. Perlman
David C. Perlman
JRJennifer Reed
Jennifer Reed
DSDaniel J. Smith
Daniel J. Smith
HHHolly Hagan
Holly Hagan
Introduction: Systematic reviews are useful for synthesizing data on various health conditions and for identifying gaps in available data. In the US, the main risk group for hepatitis C virus (HCV) infection is people who use drugs (PWUD); as a group, PWUD have the highest prevalence of chronic HCV. While the care continuum construct has been increasingly applied to studies of HCV care among PWUD, what constitutes the steps in an HCV care continuum is not standardized. We sought to examine the range of HCV care continuum outcomes that studies reported on, to identify gaps in the literature, and to develop strategies that allowed for valuable syntheses of care continuum data. Methods: We conducted searches of electronic databases for published literature. Reports were eligible if they provided original data from 1990 to 2016 from the US, presented data on one or more HCV care continuum outcomes, and provided outcome data on PWUD as a distinct group. Results: A total of 313 full-text reports were assessed for eligibility. Of 212 potentially eligible reports, 32 (15.1%) did not present outcomes for PWUD separately from those who were non-PWUD. Among 101 eligible reports, a total of 166 care continuum outcomes were extracted; outcomes could be grouped into three categories that represent the HCV care continuum: testing (39.8%, n = 66/166); linkage to care (16.9%, n = 28/166); and treatment (43.4%, n = 72/166). Seventy-four reports (73.3%, n = 74/101) presented data on only one step. Linkage to care occurred variably after only antibody, or after antibody and viral load (VL) testing. Six (5.9%, n = 6/101) reports presented data on all three steps. Conclusion: Reports examined a variety of HCV care continuum outcomes that could be grouped into the three steps of testing, linkage to care, and treatment. The application of this care continuum model would facilitate subsequent data synthesis for program comparison and public health evaluation. Given the two-step nature of HCV testing, analyses also need to account for variation in whether linkage to care occurred after antibody testing or after sequential antibody and VL testing. Additional data are needed on the progression of PWUD through the entire care continuum.

Samuel R. FriedmanSamuel R. Friedman
Samuel R. Friedman
Leslie Denise WilliamsLeslie Denise Williams
Leslie Denise Williams
AJAshly E Jordan
Ashly E Jordan
SWSuzan Walters
Suzan Walters
DPDavid Perlman
David Perlman
JEJerel Ezell
Jerel Ezell
Structural racism is increasingly recognized as a key driver of health inequities and other adverse outcomes. This paper focuses on structural racism as an “upstream” institutionalized process, how it creates health inequities and how structural racism persists in spite of generations of efforts to end it. So far, “downstream” efforts to reduce these health inequities have had little success in eliminating them. Here, we attempt to increase public health awareness of structural racism and its institutionalization and sociopolitical supports so that research and action can address them. This paper presents both a theoretic and an analytic approach to how structural racism contributes to disproportionate rates of HIV/AIDS and related diseases among oppressed populations. We first discuss differences in disease and health outcomes among people who use drugs (PWUD) and other groups at risk for HIV from different racial and ethnic populations. The paper then briefly analyzes the history of racism; how racial oppression, class, gender and other intersectional divisions interact to create health inequities; and how structural racism is institutionalized in ways that contribute to disease disparities among people who use drugs and other people. It examines the processes, institutions and other structures that reinforce structural racism, and how these, combined with processes that normalize racism, serve as barriers to efforts to counter and dismantle the structural racism that Black, indigenous and Latinx people have confronted for centuries. Finally, we discuss the implications of this analysis for public health research and action to undo racism and to enhance the health of populations who have suffered lifetimes of racial/ethnic oppression, with a focus on HIV/AIDS outcomes.